Veru Announces Proposed Public Offering

(NASDAQ:VERU), MIAMI, FL, Oct. 29, 2025 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, announced today that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase its common […]

FormFactor, Inc. Reports 2025 Third Quarter Results

(NASDAQ:FORM), Q3 Revenue, Gross Margin and Earnings per Share Exceed the Midpoint of the Outlook Range; Expects to Deliver Higher Results in the Fourth Quarter LIVERMORE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) — FormFactor, Inc. (Nasdaq: FORM) today announced its financial results for the third quarter of fiscal 2025 ended September 27, 2025. Quarterly revenues

CPS Technologies Announces Third Quarter 2025 Financial Results

(NASDAQ:CPSH), NORTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) — CPS Technologies Corporation (NASDAQ:CPSH) (“CPS” or the “Company”) today announced financial results for the fiscal third quarter ended September 27, 2025. Third Quarter Highlights Revenue of $8.8 million, more than doubling the $4.2 million in revenue from the prior-year period, reflecting continued strong demand for the

MIMEDX Announces Record Revenue for Third Quarter 2025

(NASDAQ:MDXG), Second Consecutive Quarter of Highest Quarterly Net Sales in MIMEDX History Third Quarter Net Sales of $114 million Grew 35% Year-Over-Year Third Quarter GAAP Net Income and Diluted Earnings Per Share were $17 Million and $0.11, Respectively Third Quarter Adjusted EBITDA was $35 Million, or 31% of Net Sales Raises 2025 Net Sales Growth

BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates

(NASDAQ:BBIO), – $120.7 million in total third quarter revenue, comprised of $108.1 million of U.S. Attruby(R) net product revenue, $4.3 million from royalty revenue, and $8.3 million in license and services revenue – As of October 25, 2025, 5,259 unique patient prescriptions have been written by 1,355 unique prescribers, representing an accelerating launch driven by

TTM Technologies, Inc. Reports Third Quarter 2025 Results

(NASDAQ:TTMI), SANTA ANA, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) — TTM Technologies, Inc. (NASDAQ: TTMI) (“TTM”), a leading global manufacturer of technology products, including mission systems, radio frequency (“RF”) components, RF microwave/microelectronic assemblies, and technologically advanced printed circuit boards (“PCB”s) today reported results for the third quarter 2025, which ended on September 29, 2025. Third

Diamond Hill Appoints Diane Nordin to Its Board of Directors

Today, the Board of Directors (“Board”) of Diamond Hill Investment Group, Inc. (Nasdaq: DHIL) (“Diamond Hill”) announced the appointment of Diane Nordin, CFA, as Director. Ms. Nordin will be one of six independent directors of the Company's eight-person Board, and she will serve on the Audit Committee, the Compensation Committee and the Nominating and Governance

Princeton Bancorp Announces Third Quarter 2025 Results

Princeton Bancorp, Inc. (the “Company”) (NASDAQ:BPRN), the bank holding company for The Bank of Princeton (the “Bank”), today reported its unaudited financial condition at, and its results of operations for the quarter and nine months ended, September 30, 2025. https://mma.prnewswire.com/media/1317615/The_Bank_of_Princeton_Logo.jpg President/CEO Edward Dietzler commented on the quarter results, “The Bank achieved strong quarterly results, with

Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF

Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF GlobeNewswire October 29, 2025 TX45 improved both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PHâ€'HFrEF”) TX45 was well

Veru Announces Proposed Public Offering

Veru Announces Proposed Public Offering GlobeNewswire October 29, 2025 MIAMI, FL, Oct. 29, 2025 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, announced today that it has commenced an underwritten public offering of shares of its common

Scroll to Top